Thymosin-alpha 1 (Ta1)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Research / no approved-treatment claim
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proposed uses for thymosin-alpha 1 include immune modulation, including investigation in viral infections and as an adjunct in some cancer settings.
Evidence and authorization differ by condition and country. This is not a general immunity promise or an FDA-approved indication.
Evidence and source limits
Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.
This entry records a regulator safety assessment, not a treatment benefit or a clinical recommendation. A research-purpose-only label does not establish safety, FDA approval or permission to use a substance in people. No dosing, supplier or administration guidance is provided.
Original source: Thymosin-alpha 1 (Ta1) ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.